Genetic pathways leading to therapy-related myeloid neoplasms

Mediterranean Journal of Hematology and Infectious Diseases

Volumn 3, Issue 1, 2011, Pages

  Stoddart, Angela ^a   McNerney, Megan E ^a   Bartom, Elizabeth ^a   Bergerson, Rachel ^a   Young, David J ^a   Qian, Zhijian ^a   Wang, Jianghong ^a   Fernald, Anthony A ^a   Davis, Elizabeth M ^a   Larson, Richard A ^a   White, Kevin P ^a   Le Beau, Michelle M ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84857057070     PISSN: None     EISSN: 20353006     Source Type: Journal    
DOI: 10.4084/MJHID.2011.019     Document Type: Article

References (49)

1. Ben-Chetrit E, Godley LA, Larson R. Therapy-related myeloid leukemia. Semin Oncol. 2008; 35:418-29. doi:10.1053/j.seminoncol.2008.04.012 PMid: 18692692 PMCid:2600445
2. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, Harris NL, Le Beau MM, Hellström-Lindberg E, Tefferi A, Bloomfield CD. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009; 114:937-51. doi: 10.1182/blood-2009-03-209262 PMid: 19357394
3. Allan JM, Travis LB. Mechanisms of therapy-related carcinogenesis. Nat Rev Cancer. 2005; 5:943-55. doi:10.1038/nrc1749 PMid: 16294218
4. Smith SM, Le Beau MM, Huo D, Karrison T, Sobecks RM, Anastasi J, Vardiman JW, Rowley JD, Larson R. Clinicalcytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood. 2003; 102:43-2. doi:10.1 182/blood-2002-1 1-3343 PMid:12623843
5. Pedersen-Bjergaard J, Philip P. Balanced translocations involving chromosome bands 11q23 and 21q22 are highly characteristic of myelodysplasia and leukemia following therapy with cytostatic agents targeting at DNA-topoisomerase II. Blood. 1991; 78:1147-48. PMid:1651134
6. Zhao N, Stoffel A, Wang PW, Eisenbart JD, Espinosa R, 3rd, Larson R, Le Beau MM. Molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases to 1-1.5 Mb and preparation of a PAC-based physical map. Proc Natl Acad Sci USA. 1997; 94:6948-53. doi: 10.1073/pnas.94.13.6948
7. Fairman J, Chumakov I, Chinault AC, Nowell PC, Nagarajan L. Physical mapping of the minimal region of loss in 5qchromosome. Proc Natl Acad Sci USA. 1995; 92:7406-10. doi: 10.1073/pnas.92.16.7406
8. Boultwood J, Fidler C, Strickson AJ, Watkins F, Gama S, Kearney L, Tosi S, Kasprzyk A, Cheng JF, Jaju RJ, Wainscoat JS. Narrowing and genomic annotation of the commonly deleted region of the 5q- syndrome. Blood. 2002; 99:4638-41. doi: 10.1182/blood. V99.12.4638 PMid: 12036901
9. Lai F, Godley LA, Joslin J, Fernald AA, Liu J, Espinosa R, 3rd, Zhao N, Pamintuan L, Till BG, Larson R, Qian Z, Le Beau MM. Transcript map and comparative analysis of the 1.5-Mb commonly deleted segment of human 5q31 in malignant myeloid diseases with a del(5q). Genomics. 2001; 71:235-45. doi:10.1006/geno.2000.6414PMid:1 1161817
10. Hasserjian RP, Le Beau MM, List AF, Bennett JM, Thiele J. MDS with isolated del(5q). In: Swerdlow SH, Campo E, Harris NL, Haffe ES, Pileri SA, Stein H, Thiele, J, Vardiman JW, eds. WHO Classification of Tumours of Haematopoeitic and Lymphoid Tissues. Lyon, IARC. 2008; 102.
11. Graubert TA, M.A. Payton, Shao J, Walgren RA, Monahan RS, J.L. Frater JL, Walshauser MA, Martin MG, Kasai Y, Walter MJ. Integrated genomic analysis implicates haploinsufficiency of multiple chromosome 5q31.2 genes in de novo myelodysplastic syndromes pathogenesis. Plos One. 2009; 4:e4583. doi:10.1371/journal.pone.0004583 PMid:19240791 PMCid:2642994
12. Shannon KM, Le Beau MM. Cancer: hay in a haystack. Nature 2008; 451:252-53. doi: 10.1038/451252a PMid:18202630
13. Ebert BL, Pretz J, Bosco J, Chang CY, Tamayo P, Galili N, Raza A, Root DE, Attar E, Ellis SR, Golub TR. Identification of RPS14 as a 5q- syndrome gene by RNA interference screen. Nature. 2008; 451:335-39. doi:10.1038/nature06494 PMid: 18202658
14. Joslin JM, Fernald AA, Tennant TR, Davis EM, Kogan SC, Anastasi J, Crispino JD, Le Beau MM, Haploinsufficiency of EGR1, a candidate gene in the del(5q), leads to the development of myeloid disorders. Blood. 2007; 110:719-26. doi:10.1182/blood-2007-01-068809 PMid: 17420284 PMCid: 1924479
15. Sportoletti P, S. S. Grisendi S, Majid SM, Cheng K, Clohessy JG, Viale A, Teruya-Feldstein J, Pandolfi PP. Npm1 is a haploinsufficient suppressor of myeloid and lymphoid malignancies in the mouse. Blood. 2008; 111:3859-62. doi:10.1182/blood-2007-06-098251 PMid:18212245 PMCid:2275037
16. Wang J, Fernald AA, Anastasi J, Le Beau MM, Qian Z. Haploinsufficiency of Apc leads to ineffective hematopoiesis. Blood. 2010;115:3481-88. doi: 10.1182/blood-2009-11-251835 PMid:20065296
17. Liu TX, Becker MW, Jelinek J, Wu WS, Deng M, Mikhalkevich N, Hsu K, Bloomfield CD, Stone RM, DeAngelo DJ, Galinsky IA, Issa JP, Clarke MF, Look AT. Chromosome 5q deletion and epigenetic suppression of the gene encoding alpha-catenin (CTNNA1) in myeloid cell transformation. Nat Med. 2007; 13:78-83. doi:10.1038/nm1512 PMid:17159988
18. Chen TH, Kambal A, Krysiak K, Walshauser MA, Raju G, Tibbitts JF, Walter MJ. Knockdown of Hspa9, a del(5q31.2) gene, results in a decrease in hematopoietic progenitors in mice. Blood. 2011 Feb 3;117(5): 1530-9. Epub 2010 Dec 1. PMID: 21123823
19. Eisenmann KM, Dykema KJ, Matheson SF, Kent NF, DeWard AD, West RA, Tibes R, Furge KA, Alberts AS. 5qmyelodysplastic syndromes: chromosome 5q genes direct a tumor suppression network sensing actin dynamics. Oncogene. 2009; 28:3429-41. progenitors in mice. Blood. 2011; 117:1530-39.
20. Barlow JL, Drynan LF, Hewett DR, Holmes LR, Lorenzo-Abalde S, Lane AL, Jolin HE, Pannell R, Middleton AJ, Wong SH, Warren AJ, Wainscoat JS, Boultwood J, McKenzie AN. A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q- syndrome. Nat Med. 2009;16:59-66. doi:10.1038/nm.2063 PMid:19966810 PMCid:2803774
21. Starczynowski DT, Kuchenbauer F, Argiropoulos B, Sung S, Morin R, Muranyi A, Hirst M, Hogge D, Marra M, Wells RA, Buckstein R, Lam W, Humphries RK, Karsan A. Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype. Nat Med. 2010; 16:49-58. doi:10.1038/nm.2054 PMid: 19898489
22. Kumar M, Narla A, Nonami A, Ball B, Chin C, Chen C, Kutok JL, Galili N, Raza A, Attar EC, Gilliland DG, Jacks T, Ebert BL. Coordinate loss of a microRNA mir145 and a protein-coding gene RPS14 cooperate in the pathogenesis of 5q- Syndrome. Blood. 2009; 114:947.
23. Shiseki M, Kitagawa Y, Wang YH, Yoshinaga K, Kondo T, Kuroiwa H. Lack of nucleophosmin mutation in patients with myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities. Leukaemia Lymphoma. 2007; 48:2141-44. doi:10.1080/10428190701615900 PMid:17990177
24. Mikhalkevich N, and Becker MW. Alpha-catenin is dispensible for normal hematopoietic stem cell function. Blood. 2009; 114: abstract 1438.
25. Qian Z, Chen L, Fernald AA, Williams BO, Le Beau MM. A critical role for Apc in hematopoietic stem and progenitor cell survival. J Exp Med. 2008; 205:2163-75. doi:10.1084/jem.20080578 PMid:18725524 PMCid:2526209
26. Sukhatme VP, Cao XM, Chang LC, Tsai-Morris CH, Stamenkovich D, Ferreira PC, Cohen DR, Edwards SA, Shows TB, Curran TA, Le Beau MM, Adamson ED. A zinc fingerencoding gene coregulated with c-fos during growth and differentiation, and after cellular depolarization. Cell. 1988; 53:37-43. doi: 10.1016/0092-8674(88)90485-0
27. Baron V, Adamson ED, Calogero A, Ragona G, Mercola D. The transcription factor Egr1 is a direct regulator of multiple tumor suppressors including TGFbeta1, PTEN, p53, and fibronectin. Cancer Gene Ther. 2006; 13:115-124. doi: 10.1038/sj.cgt.7700896 PMid: 16138117 PMCid:2455793
28. Min IM, Pietramaggiori G, Kim FF, Passegué E, Stevenson KE, Wagers AJ. The transcription factor EGR1 controls both the proliferation and localization of hematopoietic stem cells. Cell Stem Cell. 2008; 10:380-91. doi:10.1016/j.stem.2008.01.015 PMid: 18397757
29. Wolff L, Koller R, Hu X, Anver MR. A Moloney murine leukemia virus-based retrovirus with 4070A long terminal repeat sequences induces a high incidence of myeloid as well as lymphoid neoplasms. J Virol. 2003; 77:4965-71. doi:10.1128/JVI. 77.8.4965-4971.2003 PMid: 12663802 PMCid:152129
30. Lugthart S, van Drunen E, van Norden Y, van Hoven A, Erpelinck CAJ, Valk PJM, Beverloo BH, Löwenberg B, Delwel R. High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated. Blood. 2008; 111:4329-37. doi:10.1182/blood-2007-10-1 19230 PMid: 18272813
31. Gröschel S, Lugthart S, Schlenk RF, Valk PJM, Eiwen K, Goudswaard C, van Putten WJL, Kayser S, Verdonck LF, Lübbert M, Ossenkoppele G-J, Germing U, Schmidt-Wolf I, Schlegelberger B, Krauter J, Ganser A, Döhner H, Löwenberg B, Döhner K, Delwel R. High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities. J Clin Onc. 2010; 28:2101-7. doi:10.1200/JCO.2009.26.0646 PMid:20308656
32. Senyuk V, Sinha KK, Li D, Rinaldi CR, Yanamandra S, Nucifora G. Repression of RUNX1 activity by EVI1: A new role of EVI1 in leukemogenesis. Can Res. 2007; 67:5658-66. doi:10.1158/0008-5472.CAN-06-3962 PMid: 17575132
33. Laricchia-Robbio L, Premanand K, Rinaldi CR, Nucifora G. EVI1 impairs yyelopoiesis by deregulation of PU. 1 function. Can Res. 2009; 69:1633-42. doi:10.1158/0008-5472.CAN-08-2562 PMid: 19208846
34. Laslo P, Spooner CJ, Warmflash A, Lancki DW, Lee HJ, Sciammas R, Gantner BN, Dinner AR, Singh H. Multilineage transcriptional priming and determination of alternate hematopoietic cell fates. Cell. 2006; 126:755-66. doi:10.1016/j.cell.2006.06.052 PMid: 16923394
35. Side LE, Curtiss NP, Teel K, Kratz C, Wang PW, Larson R, Le Beau MM, Shannon KM. RAS, FLT3, and TP53 mutations in therapy-related myeloid malignancies with abnormalities of chromosomes 5 and 7. Genes Chromosomes Cancer. 2004; 39:217-23. doi: 10.1002/gcc. 10320 PMid:14732923
36. Bacher U, Haferlach T, Kern W, Haferlach C, Schnittger S. A comparative study of molecular mutations in 381 patients with myelodysplastic syndrome and in 4130 patients with acute myeloid leukemia. Haematologica. 2007; 92:744-52. doi: 10.3324/haematol. 10869 PMid: 17550846
37. Chen CY, Lin LI, Tang JL, Ko BS, Tsay W, Chou WC, Yao M, Wu SJ, Tseng MH, Tien HF. RUNX1 gene mutation in primary myelodysplastic syndrome--the mutation can be detected early at diagnosis or acquired during disease progression and is associated with poor outcome. Br J Haematol. 2007; 139:405-14. doi:10.1 111/j. 1365-2141.2007.06811.x PMid:17910630
38. Christiansen DH, Andersen MK, Pedersen-Bjergaard J. Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor prognosis. J Clin Oncol. 2001; 19:1405-13. PMid: 11230485
39. Christiansen DH, Andersen MK, Pedersen-Bjergaard J. Methylation of p15INK4B is common, is associated with deletion of genes on chromosome arm 7q and predicts a poor prognosis in therapy-related myelodysplasia and acute myeloid leukemia. Leukemia. 2003; 17:1813-19. doi:10.1038/sj.leu.2403054 PMid: 12970781
40. Leone G, Pagano L, Ben-Yehuda D, Voso MT. Therapy-related leukemia and myelodysplasia: susceptibility and incidence. Haematologica. 2007; 92:1389-98. doi: 10.3324/haematol. 11034 PMid: 17768113
41. ten Bosch JR, Grody WW. Keeping up with the next generation: Massively parallel sequencing in clinical diagnostics. J Mol Diagn. 2008; 10:484-92. doi: 10.2353/jmoldx.2008.080027 PMid: 18832462 PMCid:2570630
42. Ley TJ, Mardis ER, Ding L, Fulton B, McLellan MD, Chen K, Dooling D, Dunford-Shore BH, McGrath S, Hickenbotham M, Cook L, Abbott R, Larson DE, Koboldt DC, Pohl C, Smith S, Hawkins A, Abbott S, Locke D, Hillier LW, Miner T, Fulton L, Magrini V, Wylie T, Glasscock J, Conyers J, Sander N, Shi X, Osborne JR, Minx P, Gordon D, Chinwalla A, Zhao Y, Ries RE, Payton JE, Westervelt P, Tomasson MH, Watson M, Baty J, Ivanovich J, Heath S, Shannon WD, Nagarajan R, Walter MJ, Link DC, Graubert TA, DiPersio JF, Wilson RK. DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature. 2008; 456:66-72. PMid:18987736 PMCid:2603574
43. Mardis ER, Ding L, Dooling DJ, Larson DE, McLellan MD, Chen K, Koboldt DC, Fulton RS, Delehaunty KD, McGrath SD, Fulton LA, Locke DP, Magrini VJ, Abbott RM, Vickery TL, Reed JS, Robinson JS, Wylie T, Smith SM, Carmichael L, Eldred JM, Harris CC, Walker J, Peck JB, Du F, Dukes AF, Sanderson GE, Brummett AM, Clark E, McMichael JF, Meyer RJ, Schindler JK, Pohl CS, Wallis JW, Shi X, Lin L, Schmidt H, Tang Y, Haipek C, Wiechert ME, Ivy JV, Kalicki J, Elliott G, Ries RE, Payton JE, Westervelt P, Tomasson MH, Watson MA, Baty J, Heath S, Shannon WD, Nagarajan R, Link DC, Walter MJ, Graubert TA, Dipersio JF, Wilson RK, Ley TJ. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med. 2009; 361:1058-66. doi:10.1056/NEJMoa0903840 PMid: 19657110
44. Pan Q, Shai O, Lee LJ, Frey BJ, Blencowe BJ. Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. Nat Genet. 2008; 40:1413-5. doi:10.1038/ng.259 PMid: 18978789
45. Marioni JC, Mason CE, Mane SM, Stephens M, Gilad Y. RNAseq: an assessment of technical reproducibility and comparison with gene expression arrays. Genome Res. 2008; 18:1509-17. doi:10.1101/gr.079558.108PMid:18550803 PMCid:2527709
46. Zhao Q, Caballero OL, Levy S, Stevenson BJ, Iseli C, de Souza SJ, Galante PA, Busam D, Leversha MA, Chadalavada K, Rogers YH, Venter JC, Simpson AJ, Strausberg RL. Transcriptome-guided characterization of genomic rearrangements in a breast cancer cell line. Proc Natl Acad Sci USA. 2009; 106:1886-91. doi:10.1073/pnas.0812945106 PMid: 19181860 PMCid:2633215
47. Shah SP, Kobel M, Senz J, Morin RD, Clarke BA, Wiegand KC, Leung G, Zayed A, Mehl E, Kalloger SE, Sun M, Giuliany R, Yorida E, Jones S, Varhol R, Swenerton KD, Miller D, Clement PB, Crane C, Madore J, Provencher D, Leung P, DeFazio A, Khattra J, Turashvili G, Zhao Y, Zeng T, Glover JN, Vanderhyden B, Zhao C, Parkinson CA, Jimenez-Linan M, Bowtell DD, Mes-Masson AM, Brenton JD, Aparicio SA, Boyd N, Hirst M, Gilks CB, Marra M, Huntsman DG. Mutation of FOXL2 in granulosa-cell tumors of the ovary. N Engl J Med. 2009; 360:2719-29. doi:10.1056/NEJMoa0902542 PMid: 19516027
48. Pedersen-Bjergaard J, Andersen MK, Christiansen DH, Nerlov C. Genetic pathways in therapy-related myelodysplasia and acute myeloid leukemia. Blood. 2002; 99:1909-12. doi: 10.1182/blood. V99.6.1909 PMid: 11877259
49. Qian Z, Fernald AA, Godley LA, Larson R, Le Beau MM. Expression profiling of CD34+ hematopoietic stem/progenitor cells reveals distinct subtypes of therapy-related acute myeloid leukemia. Proc Natl Acad Sci USA. 2002; 99:14925-30. doi:10.1073/pnas.222491799 PMid:12417757 PMCid:137521